消化系统神经内分泌癌免疫治疗研究现状

The Advance in Research into Immunotherapy for Neuroendocrine Carcinoma of Digestive System

神经内分泌肿瘤是少见的异质性肿瘤,不同病理类型、分化程度、分级和分期,治疗和转归存在很大差异。其中晚期神经内分泌癌恶性度高、预后差、可选药物较少、缺乏有效治疗手段。免疫治疗是近几年肿瘤治疗领域的最重要的突破,在多种实体瘤中显示出较好疗效。以程序性死亡受体1及其配体(programmed cell death 1/programmed cell death⁃ligand 1,PD⁃1/PD⁃L1)单抗为代表的免疫治疗在神经内分泌癌治疗中的作用,国内外也进行了大量探索性研究,这些研究结果对目前免疫治疗在神经内分泌癌临床应用提供了指导,也为未来相关研究开展提供了重要参考。本文对该领域的主要研究数据进行了总结和分析。

Gastroenteropancreatic neuroendocrine neoplasm(GEP⁃NEN)is a rare heterogeneous tumor.The heterogeneity in pathology,differentiation,grade and clinical stages results in different prognosis and treat⁃ment strategy.Patients with recurrent or metastatic NEN have limited treatment options and poor prognosis.Programmed cell death 1(PD⁃1)blockade has played indispensable roles in management of cancers recently.Immunotherapy is being explored in NENs in the world with emerging clinical trials.The results of the trials provide evidence and guidance in the application of NEC.The article analizes and summarizes of the findings of major investigations in this field.